C4 is latest preclinical protein degradation IPO with big aftermarket gain

Public investors again showed their appetite for protein degradation companies Friday, as C4’s upsized IPO was the largest and best-received of three new NASDAQ listings. 

Shares of C4 Therapeutics Inc. (NASDAQ:CCCC), a preclinical company based in Watertown, Mass., finished the day with a valuation above $1 billion, with its shares rising 34% to $25.49...